Skyrizi (Risankizumab)
Provider Summary
Primary Uses
Plaque psoriasis and psoriatic arthritis; also used for Crohn’s disease/ulcerative colitis per labeled indications and payer criteria.
Mechanism of action
Monoclonal antibody targeting IL‑23 p19 subunit.
Pre-treatment / baseline requirements
Screen for active infection; TB screening (IGRA/PPD) and hepatitis B screening are commonly required for many biologics; baseline CBC and CMP/LFTs are often requested; review vaccination status (avoid live vaccines during therapy per PI); confirm pregnancy status when clinically appropriate; review prior biologic exposure and infection history.
Common side effects
Upper respiratory infection, headache, fatigue, injection-site reactions.
Serious adverse risks / Key risks
Serious infections; hypersensitivity.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Plaque psoriasis and psoriatic arthritis; also used for Crohn’s disease/ulcerative colitis per labeled indications and payer criteria.
How it works
Targets IL‑23 to reduce inflammation.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Upper respiratory infection, headache, fatigue, injection-site reactions.
Get urgent help for
Serious infections; hypersensitivity.
On treatment day
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.